Immunovant, Inc. Common Stock (IMVT) Stock Price
IMVTStock
$26.73+53.53%52W
Market Cap$5.52B
P/E—
PEG Ratio—
Div yield—
Beta0.94
IMVT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-9.23%
Price vs S&P 500 (4W)-26.78%
VGM Score57.52
IMVT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.61 | -$0.68 | -10.54%(-$0.06) | |
| Q1 2026 | -$0.63 | -$0.67 | -7.50%(-$0.05) | |
| Q4 2025 | -$0.69 | -$0.54 | +22.36%(+$0.15) | |
| Q3 2025 | -$0.73 | -$0.65 | +10.60%(+$0.08) | |
| Q2 2025 | -$0.67 | -$0.71 | -5.36%(-$0.04) |
IMVT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.13
4.23
4.17
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
IMVTImmunovant, Inc. Common Stock | — | — | C | — | — | — | — | $26.73 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Immunovant, Inc. Common Stock
Immunovant is a clinical-stage immunology company developing treatments for autoimmune diseases driven by pathogenic IgG antibodies. Its lead candidate, IMVT-1402, is an FcRn inhibitor designed to reduce circulating IgG levels by blocking the receptor responsible for antibody recycling. The company focuses on research, development, and manufacturing of its therapeutic pipeline targeting autoimmune indications.